Showing results (41-50 of 201) with videos related to
Sort By:
Pageof 21
Journal of Psychosocial Oncology|December 27, 2018
"I think it's a bit early for now": impact of psychological factors on drafting advance directives among cancer patientsPatrice Cannone, Pascale Tomasini, Merlin Paul, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2019
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, et al.Bulletin Du Cancer|March 20, 2026
[Summary of second-line treatment of stage IV NSCLC without oncogenic addiction]Thomas Pierret, Renaud Descourt, Romain Corre, et al.Molecular Diagnosis & Therapy|November 28, 2008
Biomarkers for malignant pleural mesothelioma: current statusLaurent Greillier, Paul Baas, John J Welch, et al.The Oncologist|November 4, 2016
Targeting the KRAS Pathway in Non-Small Cell Lung CancerPascale Tomasini, Preet Walia, Catherine Labbe, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2011
Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implicationsLama Sakr, Fabien Maldonado, Laurent Greillier, et al.Bulletin Du Cancer|September 29, 2012
[β-Human chorionic gonadotropin (HCG) dosage and lung cancer: a pitfall when screening patients for clinical trials]Nataliya Khobta, Pascale Tomasini, Marie-Eve Garcia, et al.BMC Cancer|April 5, 2024
Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method studyBertrand Mennecier, Jonathan Khalifa, Renaud Descourt, et al.Psychology, Health & Medicine|February 18, 2020
Illness representations and quality of life in French patients suffering from lung cancerNathalie Masson, Lionel Dany, Patrice Cannone, et al.Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.Pageof 21